Drugs / Recombinant Zoster Vaccine (CHO Cell)
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06851832 | Feb 2025 → Sep 2026 overdue | herpes zoster | Ab&B Bio-tech Co., Ltd.JS | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07293065 | Dec 2025 → Dec 2027 expected | herpes zoster | MAXVAX Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06654700 | Dec 2024 → May 2025 overdue | herpes zoster | MAXVAX Biotechnology Limited Liability Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06447779 | Jul 2024 → Sep 2025 overdue | herpes zoster | MAXVAX Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Zoster Vaccine (CHO Cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07293065 ↗ |
| Modality | Vaccine | “Recombinant Zoster Vaccine (CHO Cell)” NCT06447779 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT06447779 ↗ |